Prevalence and trend of ofloxacin-resistance among MDR-TB including XDR-TB cases in Ukraine

Cherenko, Svitlana; Litvinenko, N. A.

doi:10.1183/13993003.congress-2015.pa2721

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nonadherence to treatment for MDR-TB regimens was frequently due to adverse events (81%) [ 79 ]. A high rate of pre-XDR-TB due to fluoroquinolone resistance was noted in Karachi, Pakistan (363 out of 919 patients with MDR-TB) [ 80 ], and Kiev, Ukraine [ 81 ]. Rates of cure of XDR-TB continue to be similar to those reported with no treatment in the pre-antibiotic era [ 81 ].…”

Section: Tuberculosismentioning

confidence: 99%

“…A high rate of pre-XDR-TB due to fluoroquinolone resistance was noted in Karachi, Pakistan (363 out of 919 patients with MDR-TB) [ 80 ], and Kiev, Ukraine [ 81 ]. Rates of cure of XDR-TB continue to be similar to those reported with no treatment in the pre-antibiotic era [ 81 ]. There were several presentations noting the outpatient management of M/XDR-TB, although all were evaluated in terms of patient treatment outcomes, which were not different [ 82 ], rather than transmission of disease.…”

Section: Tuberculosismentioning

confidence: 99%

See 1 more Smart Citation

The best of respiratory infections from the 2015 European Respiratory Society International Congress

Polverino

Bothamley

Goletti³

et al. 2016

ERJ Open Res

View full text Add to dashboard Cite

The breadth and quality of scientific presentations on clinical and translational research into respiratory infections at the 2015 European Respiratory Society (ERS) International Congress in Amsterdam, the Netherlands, establishes this area as one of the leadings fields in pulmonology. The host–pathogen relationship in chronic obstructive pulmonary disease, and the impact of comorbidities and chronic treatment on clinical outcomes in patients with pneumonia were studied. Various communications were dedicated to bronchiectasis and, in particular, to different prognostic and clinical aspects of this disease, including chronic infection with Pseudomonas and inhaled antibiotic therapy. Recent data from the World Health Organization showed that Europe has the highest number of multidrug-resistant tuberculosis cases and the poorest countries have the least access to suitable treatments. Latent tuberculosis and different screening programmes were also discussed with particular attention to risk factors such as HIV infection and diabetes. Several biomarkers were proposed to distinguish between active tuberculosis and latent infection. Major treatment trials were discussed (REMOX, RIFQUIN and STREAM). The possibility of once-weekly treatment in the continuation phase (RIAQUIN) was especially exciting. The continuing rise of Mycobacterium abscessus as a significant pathogen was noted. This article reviews some of the best contributions from the Respiratory Infections Assembly to the 2015 ERS International Congress.

show abstract